



Article

Characterization of Nucleoside Reverse Transcriptase Inhibitor-Associated Mutations in the RNase H Region of HIV-1 Subtype C Infected Individuals

Sinaye Ngcapu ^{1,2,*}, Kristof Theys ^{3,†} , Pieter Libin ^{3,4}, Vincent C. Marconi ⁵, Henry Sunpath ⁶, Thumbi Ndung'u ^{1,7,8,9}  and Michelle L. Gordon ¹

¹ HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Private Bag X7, Congella, Durban 4013, South Africa; Ndungu@ukzn.ac.za (T.N); Tarinm@ukzn.ac.za (M.L.G.)

² Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Private Bag X7, Congella, Durban 4013, South Africa

³ Rega Institute for Medical Research, Department of Microbiology and Immunology, KU Leuven–University of Leuven, 3000 Leuven, Belgium; kristof.theys@kuleuven.be (K.T.); pieter.libin@vub.ac.be (P.L.)

⁴ Artificial Intelligence Lab, Department of Computer Science, Vrije Universiteit Brussel, Brussels, 1050 Elsene, Belgium

⁵ Division of Infectious Disease, Emory University School of Medicine, Atlanta, GA 30322, USA; vcmarco@emory.edu

⁶ Infectious Diseases Unit, Nelson Mandela School of Medicine, University of KwaZulu-Natal, Private Bag X7, Congella, Durban 4013, South Africa; henrysunpath@yebo.co.za

⁷ Africa Health Research Institute, University of KwaZulu-Natal, Private Bag X7, Congella, Durban 4013, South Africa

⁸ Ragon Institute of MGH, MIT and Harvard University, Cambridge, MA 01239, USA

⁹ Max Planck Institute for Infection Biology, Chariteplatz, D-10117 Berlin, Germany

* Correspondence: sinaye.ngcapu@caprisa.org; Tel.: +27-31-260-4694; Fax: +27-31-260-4566

† These authors contributed equally to this work.

Received: 26 September 2017; Accepted: 4 November 2017; Published: 8 November 2017

Abstract: The South African national treatment programme includes nucleoside reverse transcriptase inhibitors (NRTIs) in both first and second line highly active antiretroviral therapy regimens. Mutations in the RNase H domain have been associated with resistance to NRTIs but primarily in HIV-1 subtype B studies. Here, we investigated the prevalence and association of RNase H mutations with NRTI resistance in sequences from HIV-1 subtype C infected individuals. RNase H sequences from 112 NRTI treated but virologically failing individuals and 28 antiretroviral therapy (ART)-naive individuals were generated and analysed. In addition, sequences from 359 subtype C ART-naive sequences were downloaded from Los Alamos database to give a total of 387 sequences from ART-naive individuals for the analysis. Fisher's exact test was used to identify mutations and Bayesian network learning was applied to identify novel NRTI resistance mutation pathways in RNase H domain. The mutations A435L, S468A, T470S, L484I, A508S, Q509L, L517I, Q524E and E529D were more prevalent in sequences from treatment-experienced compared to antiretroviral treatment naive individuals, however, only the E529D mutation remained significant after correction for multiple comparison. Our findings suggest a potential interaction between E529D and NRTI-treatment; however, site-directed mutagenesis is needed to understand the impact of this RNase H mutation.

Keywords: HIV-1; RNase H; resistance; mutations; NRTIs

1. Introduction

South Africa is experiencing one of the world's most devastating HIV-1 epidemics, with an estimated 18.9% of the adult population infected with HIV-1 at the end of 2016 [1]. As over 3 million people had received antiretroviral therapy (ART) by 2016 [1], South Africa has the largest ART programme worldwide where nucleoside reverse transcriptase inhibitors (NRTIs) make up the backbone in recommended first- and second-line regimens [2,3]. While the prevalence of HIV-1 drug resistance is decreasing in developed countries, the up-scale ART in low and middle income African countries will most likely coincide with an increased emergence of HIV-1 drug resistance.

Most HIV-1 drug resistance studies have focused on HIV-1 subtype B, the dominant subtype in developed countries [4,5], but an increased awareness of non-B subtypes in the last decade has shown that HIV-1 subtypes can differ in the mode and tempo of drug resistance pathways [6]. To date, for any subtype, most of the mutations identified to be associated with decreased treatment response have been described for the N-terminal half that corresponds to the polymerase region, up to the first 334 amino acids [7]. In contrast, the C-terminal RT region, encompassing the connection and RNase H domains, has historically been less well characterized in the context of drug resistance [7,8]; however, studies on subtype B-infected individuals suggested that mutations in the RNase H domain can increase NRTI resistance [9–13].

Data indicating whether similar mutations develop under NRTI drug selection pressure in the RNase H domain of HIV-1 non-B subtype viruses is limited [7,8]. Given the increasing accessibility of ART in South Africa, where subtype C prevails, we investigated the emergence of mutations in the RNase H domain of the subtype C virus in the context of during NRTI treatment.

2. Materials and Methods

2.1. Study Cohort

HIV-1 subtype C sequences spanning the entire RNase H region (RT codons 431–560) were obtained from 112 ART-experienced and 28 ART-naive patients enrolled in the South African Resistance Cohort Study (SARCS), McCord Hospital, and the Paediatric Tropism Study, King Edward VIII Hospital, Durban, South Africa, respectively. The SARCS study was a prospective study assessing the prevalence of drug resistance after virologic failure in patients on combined antiretroviral therapy (cART) between January 2005 and August 2006 [14] and the Paediatric Tropism study was a prospective paediatric study between August 2008 and January 2010 [15]. All ART-experienced patients received two NRTIs either stavudine (d4T) or zidovudine (AZT) plus lamivudine (3TC) and a non-nucleoside reverse transcriptase inhibitor (NNRTI), either efavirenz (EFV) or nevirapine (NVP). Participants who experienced virologic failure were defined according to clinical, immunological, and virological criteria outlined in the South African guidelines for the management of HIV in children and adults [2]. Participants receiving second line ART drug regimen were excluded in this study. This study was approved by the Biomedical Research Ethics Committee of the University of KwaZulu-Natal (Ref: BE 106/09).

2.2. Amplification, Sequencing and Phylogenetic Analyses of the RNase H Domain

Viral RNA was isolated from 140 µL of plasma using the QIAamp RNA kit (QIAGEN Services, Inc., Germantown, MD, USA) according to the manufacturer's instructions. A 469 base pair product was amplified by nested PCR, using primers and PCR conditions as previously described [7]. PCR products were purified using the QiAquick gel purification kit (QIAGEN Inc.) according to the manufacturer's instructions. Sequences were generated using the inner primers and the BigDye v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA, USA), and run on an Applied Biosystem (ABI) 3130xl automated sequencer as previously described [7]. Sequences were assembled and edited using the Phred Phrap and Consed software programs (<http://www.phrap.org/phredphrapconsed.html>) and aligned against HXB2 reference strain [16]. The alignment was manually edited using the Genetic

Data Environment v2.2 (<http://www.bioafrica.net/GDElinux/GDEmicrobial>). HIV-1 subtype was determined by the REGA HIV-1 subtyping tool version 3 [17,18]. A maximum likelihood phylogenetic tree was built with PhyML using the GTR substitution model and 100 bootstraps [19]. In order to investigate a confounding effect of epidemiology on the identification of treatment-associated mutations, a phylogenetic tree was constructed using sequence data from which positions found to be significant in this analysis were removed.

2.3. Identification of Treatment-Related Mutations in RNase H of HIV-1 Subtype C

Treatment-related mutations in RNase H were identified by comparing mutation prevalence between viral sequences from ART-experienced patients and sequences from ART-naive patients. Additional subtype C sequences spanning the RNase H domain were obtained from the Los Alamos database, limiting to ART-naive patients from South Africa ($n = 359$) to minimize the epidemiological bias. In addition, a control dataset of subtype B sequences from ART-naive patients ($n = 1782$) spanning the RNase H domain were obtained from the Los Alamos database. Major NRTI resistance mutations were defined according to the Stanford HIV-1 drug resistance database [20]. The Fisher's exact test was used to detect mutations significantly more prevalent in ART-experienced patients, with a level of significance of 0.05. p -Values were adjusted using a False discovery rate step-down procedure to reduce false positive results [21]. Known and novel mutations were identified by comparing with NRTI-associated RNase H mutations previously identified from subtype B drug-resistance studies: K451R, D460N, L469F, T470N, T473A, N474A, Q475A, K476A/N, D488E, L491S, Q500A, Y501A/F, I505A, I506L, Q509L, K512Q, K527N, K530R, H539N, V518I, E529D, Q547K, D549N, A554S and K558E/R [7–9,11,12,22–29].

2.4. Bayesian Network Construction

Bayesian network learning was applied to identify novel NRTI resistance mutation pathways in RNase H. Mutations identified using the Fisher's exact test were included together with polymorphisms prevalent over 15% in the ART-naive population. Dependencies between mutations were learned and represented graphically as described previously [30–32]. The robustness of the network was assessed with a non-parametric bootstrap using 500 replicates.

3. Results

3.1. Prevalence of RNase H Mutations in ART-Naive Subtype C Sequences

HIV-1 subtype C viral sequences from 112 NRTI-treated and 28 ART-naive HIV-1 patients in the study cohort were amplified and sequenced. In addition, sequences from 359 subtype C ART-naive sequences were downloaded from the Los Alamos database to give a total of 387 sequences from ART-naive individuals for the analysis. No unusual clustering of the study sequences was observed, confirming that there was no cross-contamination between sequences.

We assessed the natural variability in the RNase H region of subtype C by determining the amino acid distribution of the 130 positions (from amino acid 431–560) of the ART-naive sequences (Figure 1). The analysed amino acids included the RNase H primer grip (R448, T473, N474, Q475, K476, Q500, Y501 and I505), RNase H active site (D443, E478, D498 and D549) and the RNase H sites overlapping the protease cleavage site (E438, T439, F440, Y441, V442, D443, G444 and A445) [29–32]. The RNase H primer grip and active site were well conserved, with positions 474 and 475 showing less than 1% variation, and less than 5% variation for positions 448 and 476. Furthermore, the RNase H motif E438-A445 that overlaps the protease cleavage site was well conserved. This agrees with previous studies, suggesting that any amino acid variation at these highly-conserved sites may have functional constraints on the virus in vivo [33–35]. The consensus amino acid of subtype C differed at 10 positions in RNase H (435, 452, 466, 471, 483, 491, 519, 530, 534, 554) from the consensus amino acid of subtype B (Figure 1). Interestingly, the consensus amino acid in the wild-type subtype C sequence was associated

with drug resistance in subtype B, including S491 (75.2%), K512 (93.4%), R530 (88.9%) and S554 (64.7%). Other subtype B resistance-associated mutations found in the naive subtype C sequences were: T470N (13.6%), Q509L (1.6%), K527N (27.1%) and K558R (3.8%). The full amino acid distribution per position is available as Supplementary Material (Figures S1–S3).

RnaseH subtype C

431K 432E 433P 434I 435A 436G 437A 438E 439T 440F 441Y 442V 443D 444G 445A 446A 447N 448R 449E 450T
 451K 452I 453G 454K 455A 456G 457Y 458V 459T 460D 461R 462G 463R 464Q 465K 466I 467V 468S 469L 470T
 471E 472T 473T 474N 475Q 476K 477T 478E 479L 480Q 481A 482I 483Q 484L 485A 486L 487Q 488D 489S 490G
 491S 492E 493V 494N 495I 496V 497T 498D 499S 500Q 501Y 502A 503L 504G 505I 506I 507Q 508A 509Q 510P
 511D 512K 513S 514E 515S 516E 517L 518V 519N 520Q 521I 522I 523E 524Q 525L 526I 527K 528K 529E 530R
 531V 532Y 533L 534S 535W 536V 537P 538A 539H 540K 541G 542I 543G 544G 545N 546E 547Q 548V 549D 550K
 551L 552V 553S 554S 555G 556I 557R 558K 559V 560L

RnaseH subtype B

431K 432E 433P 434I 435V 436G 437A 438E 439T 440F 441Y 442V 443D 444G 445A 446A 447N 448R 449E 450T
 451K 452L 453G 454K 455A 456G 457Y 458V 459T 460D 461R 462G 463R 464Q 465K 466V 467V 468S 469L 470T
 471D 472T 473T 474N 475Q 476K 477T 478E 479L 480Q 481A 482I 483H 484L 485A 486L 487Q 488D 489S 490G
 491L 492E 493V 494N 495I 496V 497T 498D 499S 500Q 501Y 502A 503L 504G 505I 506I 507Q 508A 509Q 510P
 511D 512K 513S 514E 515S 516E 517L 518V 519S 520Q 521I 522I 523E 524Q 525L 526I 527K 528K 529E 530K
 531V 532Y 533L 534A 535W 536V 537P 538A 539H 540K 541G 542I 543G 544G 545N 546E 547Q 548V 549D 550K
 551L 552V 553S 554A 555G 556I 557R 558K 559V 560L




Figure 1. Natural variability in 387 RNase H subtype C sequences and in 1782 RNase H subtype B sequences from ART-naive patients. The consensus amino acid at each position is coloured according to frequency.

3.2. Prevalence of RNase H Mutations in NRTI-Treatment-Experienced Compared to ART-Naive Subtype C Sequences

We searched for treatment-associated mutations by comparing the prevalence of amino acids at each position between sequences from 387 ART-naive and 112 NRTI-experienced patients. The most frequently observed reverse transcriptase (RT) drug resistance mutations in NRTI-experienced patients were M184I/V (64.2%), D67N (25.9%), K70R (19.6%), K219Q/E (17.9%) and T215Y/F (13.4%).

Other known NRTI-elicited mutations were less prevalent (<1%). A total of 9 mutations in RNase H were found positively selected in ART-experienced patients compared to ART-naive patients, these included respectively A435L (5.4% vs. 1.0%), S468A (5.4% vs. 0.5%), T470S (39.3% vs. 26.1%), L484I (11.6% vs. 3.1%), A508S (6.3% vs. 1.0%), Q509L (4.5% vs. 0.7%), L517I (14.3% vs. 4.6%), Q524E (29% vs. 15.5%) and E529D (20.5% vs. 2.3%) (Figure 2). Only E529D remained significant after adjusting for multiple comparisons ($p < 0.001$). In contrast, mutations E432D, A446S and P537Q occurred at a lower frequency in the treatment-experienced versus naive sequences.




Figure 2. The frequency (%) of treatment-associated mutations in antiretroviral therapy (ART)-naive patients and ART-experienced patients.

3.3. Dependencies between RNase H domain Mutations

We explored associations between the presence of natural polymorphisms, the emergence of mutations and NRTI treatment experience using Bayesian network learning. Figure 3 shows that mutations in the RNase H domain did not interact with any known NRTI-elicited mutations. A direct robust interaction was observed between treatment experience (eRT) and known NRTI-elicited mutations M184I/V and K70E/R. A strong interaction also existed between treatment experience and mutation E529D in the RNase H domain, independently of other mutations. Interactions between treatment experience and RNase H domain mutations S468A, A508S and L517I were less robust. RNase H mutation S468A was further strongly connected to other RNase H mutations L484I and A435L. Polymorphisms T470S and Q524E, that increased in prevalence following treatment, did not directly interact with any known NRTI-elicited mutations and/or treatment experience, indicating a potential supporting role.




Figure 3. Annotated Bayesian network, based on 500 bootstraps, showing graphically the learned associations between nodes denoting amino acids or treatment experience. An arc (arrows) represents a direct dependency between corresponding nodes and arc thickness is proportional to bootstrap support. An antagonistic arc with a wild type was treated the same as a synergistic arc with mutations at this position. Arc direction has no causal meaning, but may indicate a non-additive multivariate effect.

4. Discussion

The role and effects of mutations in the RNase H domain in contributing to NRTI failure have not been fully elucidated, particularly in non-B subtypes, with most available data describing subtype B sequences from developed countries. Here, treatment-related mutations were identified by comparing mutation frequencies in subtype C NRTI treatment-experienced sequences to those in subtype C ART naive sequences. Our findings indicate that several previously identified NRTI drug resistance mutations (435, 483, 491, 519, 530, and 554) of subtype B [7–9,11,12] represent the wild-type in subtype C, thereby warranting further characterization of their role. In our cohort, the E529D mutation was significantly more prevalent in sequences from NRTI treated patients, suggesting that it is a treatment related mutation in South African subtype C viruses.

As expected, most of the amino acids in the active site and primer grip site were conserved, as mutations in these regions impact on the functioning of RNase H [7,9]. Previous reports demonstrated by site-directed mutagenesis that mutations (N474, Q475 and Y501) in or near the primer binding site reduced RNase H cleavage specificity and modified the enzyme’s ability to remove

the polypurine tract primer. Furthermore, mutations in the RNase H sites overlapping the protease cleavage site caused defects in the virus and malfunctioning of the HIV-1 integrase enzyme [7,9]. Taken together, these findings suggest that any changes in positions closer to these functionally important sites may lead to RNase H and RT enzyme inefficiency.

None of the resistance-associated mutations in RNase H (L469F, K527N, Q509L and K558E/R) identified for subtype B [7] were found to be significant among treated compared to naive participants in this cohort. Codons L469 and K527 were highly polymorphic in both ART-naive and treatment-experienced sequences, with the exception of position K558 that showed a low degree of variability in both treated and treatment naive sequences. Additionally, this study did not observe any association between K558 and thymidine analog mutations (TAMs) and this in contrast with previous studies that showed combination of K558 and TAMs conferring resistance to thymidine analog drugs. Furthermore, mutations at RNase H positions 435, 483, 491, 519, 530, and 554 previously reported to be associated with NRTI drug resistance in subtype B studies were found in both naive and treated sequences at high prevalence, indicating that these are naturally occurring polymorphisms in subtype C. Previous studies have reported that position 469, 470 and 554 are near the RNase H primer grip and active site, suggesting that any changes in these positions could reduce the RNase H activity by indirectly modifying the interaction between the C-terminal of RT and its nucleic acid substrate [12,13]. In combination with TAMs and A371V, Q509L mutation reduced AZT susceptibility about 10- to 50-fold in vitro [19,20]. Overall, our study demonstrated similar subtype difference between subtype B and C in protease and polymerase domains [36], suggesting that these differences could affect replication capacity and cytopathogenicity of subtype C sequences compared to subtype B sequences, or result from a confounding effect of shared history.

Resistance pathways to NRTI treatment were further investigated using Bayesian Network Learning. The presence of RNase H mutation E529D was directly dependent on whether or not the patient received an NRTI, supporting its role in the development of NRTI resistance. Recent work by Barral et al. (2016) also observed a prevalence increase of E529D following treatment administration in subtype C patients in Brazil [8], further supporting our findings. Other RNase H mutations were also connected to treatment experience, although the support for these connections was low. Phylogenetic analyses indicated that the emergence of E529D patients did not result from a shared ancestry but rather from multiple independent selection events. Unfortunately, this study was unable to directly link the presence of E529D with a specific antiretroviral drug since we could not differentiate d4T from AZT users within the treated group. However, the exact role of E529D needs to be further investigated using site-directed mutagenesis as this mutation can either increase phenotypic resistance or restore enzymatic activity.

5. Conclusions

This study identified differences in the mutational response of RT to NRTI treatment between subtype B and South African subtype C, with novel mutation E529D, in particular, strongly associated with treatment experience. Results obtained from this study strongly support the need for additional research on the role of the RNase H region in the development of HIV-1 drug resistance, using larger association studies and drug susceptibility assays. Findings from subtype B studies should be re-evaluated to exclude a confounding effect of epidemiology on the identification of mutations.

Supplementary Materials: The following are available online at www.mdpi.com/1999-4915/9/11/330/s1, Figure S1: Amino Acids distribution in the RNase H Domain Sequences From Treatment Experienced HIV-1 Subtype C Infected Patients. Figure S2: Amino Acids distribution in the RNase H Domain Sequences From Treatment Naïve HIV-1 Subtype. Figure S3: Amino Acids distribution in the RNase H Domain Sequences From Treatment Naïve HIV-1 Subtype B Infected Patients.

Acknowledgments: We would like to thank Keshni Hiramani and Taryn Green for the laboratory support and Andrea-Clemencia Pineda-Pena for her support in collecting sequence data from the Los Alamos Database and for help with the phylogenetic analysis. This study was funded by grants from the International Maternal Paediatric Adolescent AIDS Clinical Trials (IMPAACT) Specialty Laboratory Bi-Annual Evaluation. Partial funding was also provided by a South African Research Chairs grant provided by the National Research Foundation and an International Early Career Scientist award from the Howard Hughes Medical Institute to Thumbi Ndung'u. Sinaye Ngcapu was supported by Columbia University-Southern African Fogarty AIDS International Training

and Research (AITRP) Program (grant # D43TW00231). Kristof Theys was funded with a postdoctoral fellowship from the Research Foundation Flanders (FWO). Pieter Libin was supported by the Vrije Universiteit Brussel (VUB) research council (VUB/OZR2714) and a PhD grant of the Research Foundation Flanders (FWO). Open Access of this article has been made possible through support from the Victor Daitz Information Gateway, an initiative of the Victor Daitz Foundation and the University of KwaZulu-Natal.

Author Contributions: Sinaye Ngcapu, Michelle L. Gordon and Thumbi Ndung'u conceived and designed the analysis and Sinaye Ngcapu, Kristof Theys and Pieter Libin performed the analyses. Vincent C. Marconi and Henry Sunpath were principal and co-principal investigators of the South African Resistance Cohort Study, respectively. All authors have contributed to the interpretation and discussion of the results, and writing of the manuscript.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. UNAIDS, Global AIDS Update. 2016. Available online: <http://www.unaids.org/en/resources/documents/2016/Global-AIDS-update-2016> (accessed on 7 June 2017).
2. Department of Health National Comprehensive HIV and AIDS plan statistics; South Africa, 2008. Available online: <http://www.health.gov.za/edp.php> (accessed on 7 June 2017).
3. Meintjes, G.; Moorhouse, M.A.; Carmona, S.; Davies, N.; Dlamini, S.; van Vuuren, C.; Manzini, T.; Mathe, M.; Moosa, Y.; Nash, J.; et al. Adult antiretroviral therapy guidelines 2017. *S. Afr. J. HIV Med.* **2017**, *18*, 1–24. [[CrossRef](#)]
4. Hemelaar, J.; Gouws, E.; Ghys, P.D.; Osmanov, S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. *AIDS* **2006**, *20*, W13–W23. [[CrossRef](#)] [[PubMed](#)]
5. Taylor, B.S.; Sobieszczyk, M.E.; McCutchan, F.E.; Hammer, S.M. The challenge of HIV-1 subtype diversity. *N. Engl. J. Med.* **2008**, *358*, 1590–1602. [[CrossRef](#)] [[PubMed](#)]
6. Martinez-Cajas, J.L.; Pai, N.P.; Klein, M.B.; Wainberg, M.A. Differences in resistance mutations among HIV-1 non-subtype B infections: A systematic review of evidence (1996–2008). *J. Int. AIDS Soc.* **2009**, *12*, 11. [[CrossRef](#)] [[PubMed](#)]
7. Santos, A.F.; Lengrubler, R.B.; Soares, E.A.; Jere, A.; Sprinz, E.; Martinez, A.M.; Silveira, J.; Sion, F.S.; Pathak, V.K.; Soares, M.A. Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients. *PLoS ONE* **2008**, *3*, e1781. [[CrossRef](#)] [[PubMed](#)]
8. Barral, M.F.M.; Sousa, A.K.P.; Santos, A.F.; Abreu, C.M.; Tanuri, A.; Soares, M.A. Identification of novel resistance-related polymorphisms in HIV-1 subtype C RT connection and RNase H domains from patients under virological failure in Brazil. *AIDS Res. Hum. Retrovir.* **2017**, *33*, 465–471. [[CrossRef](#)] [[PubMed](#)]
9. Delviks-Frankenberry, K.A.; Nikolenko, G.N.; Barr, R.; Pathak, V.K. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance. *J. Virol.* **2007**, *81*, 6837–6845. [[CrossRef](#)] [[PubMed](#)]
10. Nikolenko, G.N.; Palmer, S.; Maldarelli, F.; Mellors, J.W.; Coffin, J.M.; Pathak, V.K. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: Balance between RNase H activity and nucleotide excision. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 2093–2098. [[CrossRef](#)] [[PubMed](#)]
11. Ntemgwa, M.; Wainberg, M.A.; Oliveira, M.; Moisi, D.; Lalonde, R.; Micheli, V.; Brenner, B.G. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. *Antimicrob. Agents Chemother.* **2007**, *51*, 3861–3869. [[CrossRef](#)] [[PubMed](#)]
12. Roquebert, B.; Wirden, M.; Simon, A.; Deval, J.; Katlama, C.; Calvez, V.; Marcelin, A.G. Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naive and pre-treated HIV infected patients. *J. Med. Virol.* **2007**, *79*, 207–211. [[CrossRef](#)] [[PubMed](#)]
13. Sarafianos, S.G.; Das, K.; Tantillo, C.; Clark, A.D., Jr.; Ding, J.; Whitcomb, J.M.; Boyer, P.L.; Hughes, S.H.; Arnold, E. Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA: DNA. *EMBO J.* **2001**, *20*, 1449–1461. [[CrossRef](#)] [[PubMed](#)]
14. Marconi, V.C.; Sunpath, H.; Lu, Z.; Gordon, M.; Koranteng-Apeagyei, K.; Hampton, J.; Carpenter, S.; Giddy, J.; Ross, D.; Holst, H.; et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. *Clin. Infect. Dis.* **2008**, *46*, 1589–1597. [[CrossRef](#)] [[PubMed](#)]

15. Green, T.N.; Archary, M.; Gordon, M.L.; Padayachi, N.; Lie, Y.; Anton, E.D.; Reeves, J.D.; Grobler, A.; Bobat, R.; Coovadia, H.; et al. Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in South Africa. *AIDS Res. Hum. Retrovir.* **2012**, *28*, 324–332. [[CrossRef](#)] [[PubMed](#)]
16. Hahn, B.H.; Shaw, G.M.; Arya, S.K.; Popovic, M.; Gallo, R.C.; Wong-Staal, F. Molecular cloning and characterization of the HTLV-III virus associated with AIDS. *Nature* **1984**, *312*, 166–169. [[CrossRef](#)] [[PubMed](#)]
17. Alcántara, L.C.; Cassol, S.; Libin, P.; Deforche, K.; Pybus, O.G.; van Ranst, M.; Galvao-Castro, B.; Vandamme, A.M.; de Oliveira, T. A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. *Nucleic Acids Res.* **2009**, *37*, 634–642. [[CrossRef](#)] [[PubMed](#)]
18. Pineda-Pena, A.C.; Faria, N.R.; Imbrechts, S.; Libin, P.; Abecasis, A.B.; Deforche, K.; Gomez-Lopez, A.; Camacho, R.J.; de Oliveira, T.; Vandamme, A.M. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: Performance evaluation of the new REGA version 3 and seven other tools. *Infect. Genet. Evol.* **2013**, *19*, 337–348. [[CrossRef](#)] [[PubMed](#)]
19. Guindon, S.; Dufayard, J.F.; Lefort, V.; Anisimova, M.; Hordijk, W.; Gascuel, O. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. *Syst. Biol.* **2010**, *59*, 307–321. [[CrossRef](#)] [[PubMed](#)]
20. Rhee, S.Y.; Kantor, R.; Katzenstein, D.A.; Camacho, R.; Morris, L.; Sirivichayakul, S.; Jorgensen, L.; Brigido, L.F.; Schapiro, J.M.; Shafer, R.W. HIV-1 pol mutation frequency by subtype and treatment experience: Extension of the HIVseq program to seven non-B subtypes. *AIDS* **2006**, *20*, 643–651. [[CrossRef](#)] [[PubMed](#)]
21. Columb, M.O.; Sagadai, S. Multiple comparisons. *Curr. Anaesth. Crit. Care* **2006**, *17*, 233–236. [[CrossRef](#)]
22. Brehm, J.H.; Koontz, D.; Meteer, J.D.; Pathak, V.; Sluis-Cremer, N.; Mellors, J.W. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine. *J. Virol.* **2007**, *81*, 7852–7859. [[CrossRef](#)] [[PubMed](#)]
23. Hachiya, A.; Shimane, K.; Sarafianos, S.G.; Kodama, E.N.; Sakagami, Y.; Negishi, F.; Koizumi, H.; Gatanaga, H.; Matsuoka, M.; Takiguchi, M.; et al. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients. *Antivir. Res.* **2009**, *82*, 115–121. [[CrossRef](#)] [[PubMed](#)]
24. Nikolenko, G.N.; Delviks-Frankenberry, K.A.; Palmer, S.; Maldarelli, F.; Fivash, M.J., Jr.; Coffin, J.M.; Pathak, V.K. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 317–322. [[CrossRef](#)] [[PubMed](#)]
25. Tisdale, M.; Schulze, T.; Larder, B.A.; Moelling, K. Mutations within the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase abolish virus infectivity. *J. Gen. Virol.* **1991**, *72 Pt 1*, 59–66. [[CrossRef](#)] [[PubMed](#)]
26. Volkmann, S.; Wohrl, B.M.; Tisdale, M.; Moelling, K. Enzymatic analysis of two HIV-1 reverse transcriptase mutants with mutations in carboxyl-terminal amino acid residues conserved among retroviral ribonucleases H. *J. Biol. Chem.* **1993**, *268*, 2674–2683. [[PubMed](#)]
27. Wohrl, B.M.; Volkmann, S.; Moelling, K. Mutations of a conserved residue within HIV-1 ribonuclease H affect its exo- and endonuclease activities. *J. Mol. Biol.* **1991**, *220*, 801–818. [[CrossRef](#)]
28. Lengruber, R.B.; Delviks-Frankenberry, K.A.; Nikolenko, G.N.; Baumann, J.; Santos, A.F.; Pathak, V.K.; Soares, M.A. Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations. *J. Antimicrob. Chemother.* **2011**, *66*, 702–708. [[CrossRef](#)] [[PubMed](#)]
29. Waters, J.M.; O'Neal, W.; White, K.L.; Wakeford, C.; Lansdon, E.B.; Harris, J.; Svarovskaia, E.S.; Miller, M.D.; Borroto-Esoda, K. Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients. *Antivir. Ther.* **2009**, *14*, 231–239. [[PubMed](#)]
30. Deforche, K.; Camacho, R.; Grossman, Z.; Silander, T.; Soares, M.A.; Moreau, Y.; Shafer, R.W.; van Laethem, K.; Carvalho, A.P.; Wynhoven, B.; et al. Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. *Infect. Genet. Evol.* **2007**, *7*, 382–390. [[CrossRef](#)] [[PubMed](#)]
31. Theys, K.; Deforche, K.; Libin, P.; Camacho, R.J.; van Laethem, K.; Vandamme, A.M. Resistance pathways of human immunodeficiency virus type 1 against the combination of zidovudine and lamivudine. *J. Gen. Virol.* **2010**, *91 Pt 8*, 1898–1908. [[CrossRef](#)] [[PubMed](#)]

32. Cuypers, L.; Libin, P.; Schrooten, Y.; Theys, K.; di Maio, V.C.; Cento, V.; Lunar, M.M.; Nevens, F.; Poljak, M.; Ceccherini-Silberstein, F.; et al. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning. *Infect. Genet. Evol.* **2017**, *53*, 15–23. [[CrossRef](#)] [[PubMed](#)]
33. Arion, D.; Sluis-Cremer, N.; Min, K.L.; Abram, M.E.; Fletcher, R.S.; Parniak, M.A. Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones. *J. Biol. Chem.* **2002**, *277*, 1370–1374. [[CrossRef](#)] [[PubMed](#)]
34. Julias, J.G.; McWilliams, M.J.; Sarafianos, S.G.; Arnold, E.; Hughes, S.H. Mutations in the RNase H domain of HIV-1 reverse transcriptase affect the initiation of DNA synthesis and the specificity of RNase H cleavage in vivo. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 9515–9520. [[CrossRef](#)] [[PubMed](#)]
35. Abram, M.E.; Parniak, M.A. Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain. *J. Virol.* **2005**, *79*, 11952–11961. [[CrossRef](#)] [[PubMed](#)]
36. Iordanskiy, S.; Waltke, M.; Feng, Y.; Wood, C. Subtype-associated differences in HIV-1 reverse transcription affect the viral replication. *Retrovirology* **2010**, *7*, 85. [[CrossRef](#)] [[PubMed](#)]



© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).